Priyanka Moondra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Priyanka Moondra has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Aaron Lasker
Parkinson's Disease and Movement Disorders Center University of Pennsylvania Philadelphia Pennsylvania USA
1 shared publication- Alayne P. Meyer
Division of Genetic and Genomic Medicine Nationwide Children's Hospital Columbus Ohio USA
1 shared publication Alessandro Di Rocco
Department of Neurology, Northwell Health
1 shared publication- Alessandro Di Rocco
Department of Neurology, Movement Disorders Division, Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Long Island, NY 11542, USA
1 shared publication - Alessandro Di Rocco
Department of Neurology Northwell Health New York City New York USA
1 shared publication - Alexey Kozlenkov
VA Sequencing Collaborations United for Research and Epidemiology (seqCURE) James J. Peters VA Medical Center Bronx New York USA
1 shared publication
Latest Publications
- 16 October 2026
- Published by Wiley in Movement Disorders Clinical Practice
VPS13A Disease (Chorea‐Acanthocytosis) in Puerto Rico; New Genetic and Clinical Observations
Background: VPS13A disease is a very rare neurodegenerative disorder caused by mutations in the VPS13A gene. Its prevalence appears to be relatively high in Puerto Ricans, although limited genetic information has been available. Objectives: To describe the genetics of VPS13A disease (chorea‐acanthocytosis) in Puerto Rico. Methods: Data were obtained from Puerto Rican patients with genetically confirmed VPS13A disease. Results: Eighteen cases were identified, all carrying at least one of four mutations, c.1400_1401del, c.3556_3557dup, c.3889C>T, and c.2825‐253_2905‐374del (exon_27‐deletion); six additional single variants were detected. Seizures were the presenting symptom in 53% of patients. Conclusion: The presence of these probable founder mutations could explain the apparently increased prevalence in Puerto Rico; half of the described variants are newly described mutations and half have been previously reported. Enhanced clinical awareness of the spectrum of presenting symptoms and diagnostic clues, and improved access to genetic testing are essential for timely diagnosis in this population.
- 16 October 2026
- Published by Wiley in Movement Disorders Clinical Practice
VPS13A Disease (Chorea‐Acanthocytosis) in Puerto Rico; New Genetic and Clinical Observations
Background: VPS13A disease is a very rare neurodegenerative disorder caused by mutations in the VPS13A gene. Its prevalence appears to be relatively high in Puerto Ricans, although limited genetic information has been available. Objectives: To describe the genetics of VPS13A disease (chorea‐acanthocytosis) in Puerto Rico. Methods: Data were obtained from Puerto Rican patients with genetically confirmed VPS13A disease. Results: Eighteen cases were identified, all carrying at least one of four mutations, c.1400_1401del, c.3556_3557dup, c.3889C>T, and c.2825‐253_2905‐374del (exon_27‐deletion); six additional single variants were detected. Seizures were the presenting symptom in 53% of patients. Conclusion: The presence of these probable founder mutations could explain the apparently increased prevalence in Puerto Rico; half of the described variants are newly described mutations and half have been previously reported. Enhanced clinical awareness of the spectrum of presenting symptoms and diagnostic clues, and improved access to genetic testing are essential for timely diagnosis in this population.
- Open Access
- 25 July 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (8)
In-Patient Multimodal Intensive Neurorehabilitation and Care Improve Motor and Non-Motor Functions in the Moderately Advanced Stages of Parkinson’s Disease: A Retrospective Study in a U.S. Facility
(1) Background: Previous studies, mostly performed in European centers, have shown that in-patient multimodal intensive rehabilitation treatments lasting for two to four weeks can improve both motor and non-motor symptoms of Parkinson’s disease (PD) with long-lasting effects. Here, we ascertain the effects of a similar in-patient program in a U.S. center with a retrospective study in a cohort of 153 patients in the moderately advanced stage of PD. (2) Methods: We compared indices of motor and non-motor functions before and immediately after such treatment and investigated the possible differences between men and women. We used the available records of the Beck Depression Inventory, PDQ39, PD Sleep Scale, Timed Up and Go, Vocal Volume, Voice Handicap, and total UPDRS scores. (3) Results: We found that at the end of treatment, which lasted an average of 14 days, all outcome measures significantly improved independently of sex. (4) Conclusions: These results confirm the previous findings with a similar in-patient approach in European centers. They further suggest that this in-patient treatment is a care model that is feasible in U.S. centers and can provide a more immediate benefit to the motor function and quality of life of patients with moderately advanced PD.
- 25 July 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (8)
Open AccessIn-Patient Multimodal Intensive Neurorehabilitation and Care Improve Motor and Non-Motor Functions in the Moderately Advanced Stages of Parkinson’s Disease: A Retrospective Study in a U.S. Facility
(1) Background: Previous studies, mostly performed in European centers, have shown that in-patient multimodal intensive rehabilitation treatments lasting for two to four weeks can improve both motor and non-motor symptoms of Parkinson’s disease (PD) with long-lasting effects. Here, we ascertain the effects of a similar in-patient program in a U.S. center with a retrospective study in a cohort of 153 patients in the moderately advanced stage of PD. (2) Methods: We compared indices of motor and non-motor functions before and immediately after such treatment and investigated the possible differences between men and women. We used the available records of the Beck Depression Inventory, PDQ39, PD Sleep Scale, Timed Up and Go, Vocal Volume, Voice Handicap, and total UPDRS scores. (3) Results: We found that at the end of treatment, which lasted an average of 14 days, all outcome measures significantly improved independently of sex. (4) Conclusions: These results confirm the previous findings with a similar in-patient approach in European centers. They further suggest that this in-patient treatment is a care model that is feasible in U.S. centers and can provide a more immediate benefit to the motor function and quality of life of patients with moderately advanced PD.
- 9 July 2024
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 24 (9) , 849-863
Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington’s disease
Tardive dyskinesia (TD) and Huntington's disease (HD)-associated chorea are persistent and disabling hyperkinetic disorders that can be treated with vesicular monoamine transporter type 2 (VMAT2) inhibitors, including the recently approved once-daily (QD) formulation of deutetrabenazine (DTBZ ER). While its efficacy and safety profile have not been directly investigated, currently available data confirms bioequivalence and similar bioavailability to the twice-daily formulation (DTBZ BID). The authors briefly review the pivotal trials establishing efficacy of DTBZ for TD and HD-associated chorea, the pharmacokinetic data for bioequivalence between QD and BID dosing of DTBZ, as well as dose proportionality evidence, titration recommendations, and safety profile for DTBZ ER. Long-term data show that DTBZ is efficacious and well tolerated for the treatment of TD and HD-associated chorea. DTBZ ER likely demonstrates therapeutic equivalence with no new safety signals. Due to the lack of comparative clinical trial data, no evidence-based recommendation about choice of VMAT2 inhibitor or switching between VMAT2 inhibitors can be made about best practice. Ultimately, QD dosing may offer the chance of improved medication adherence, an important consideration in patients with complex treatment regimens and/or patients with cognitive decline.
- 9 July 2024
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 24 (9) , 849-863
Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington’s disease
Tardive dyskinesia (TD) and Huntington's disease (HD)-associated chorea are persistent and disabling hyperkinetic disorders that can be treated with vesicular monoamine transporter type 2 (VMAT2) inhibitors, including the recently approved once-daily (QD) formulation of deutetrabenazine (DTBZ ER). While its efficacy and safety profile have not been directly investigated, currently available data confirms bioequivalence and similar bioavailability to the twice-daily formulation (DTBZ BID). The authors briefly review the pivotal trials establishing efficacy of DTBZ for TD and HD-associated chorea, the pharmacokinetic data for bioequivalence between QD and BID dosing of DTBZ, as well as dose proportionality evidence, titration recommendations, and safety profile for DTBZ ER. Long-term data show that DTBZ is efficacious and well tolerated for the treatment of TD and HD-associated chorea. DTBZ ER likely demonstrates therapeutic equivalence with no new safety signals. Due to the lack of comparative clinical trial data, no evidence-based recommendation about choice of VMAT2 inhibitor or switching between VMAT2 inhibitors can be made about best practice. Ultimately, QD dosing may offer the chance of improved medication adherence, an important consideration in patients with complex treatment regimens and/or patients with cognitive decline.
- 25 April 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (17_supplem)
Functional Outcomes of an Intensive Multimodal Rehabilitation Intervention for Moderately Advanced Parkinson's Disease (P10-11.004)
Objective: To measure the impact of intensive multimodal neurorehabilitation in patients with moderately advanced with Parkinson’s disease (PD) Background: Dedicated neurorehabilitation is an essential part of the comprehensive care regimen for PD patients. Intensive multimodal therapy may be especially efficacious for motor and non-motor symptoms in moderately advanced patients, who are at higher risk of falling and losing independent function. Few studies have been conducted in inpatient setting, where pharmacological intervention and therapies can be personalized. Here we present initial functional and quality of life outcomes for patients who participated in our tailored rehabilitation program. Design/Methods: 120 patients with PD (H&Y Stage 3–4) were admitted to the Parkinson’s neurorehabilitation unit. Admission criteria included loss of independence in key life function and falls within the past year. Patients participated in a structured inpatient, personalized multidisciplinary program with an emphasis on physical, occupational, and speech therapies. The patients were also followed by Movement Disorders specialists, who tailored pharmacotherapy. Average length of stay in the program was 14.8 days. A variety of clinical and self-reported scales were completed at admission and discharge: Beck’s Depression Inventory (BDI), Sleep Scale (PDSS), Timed Up and Go (TUG), Vocal Volume, and Parkinson’s Disease Questionnaire (PDQ-39). The statistical methods utilized were two-sample paired t-tests and correlation analyses. Results: The following results were statistically significant (p≤0.05): BDI scores decreased from M=16.64 (SD±10.83) to M=12.98 (SD±9.34); PDSS scores increased from M=88.12 (SD±26.30) to M=105.5 (SD±24.47); TUG scores decreased from M=57.46 (SD±47.50) to M=40.59 (SD±33.75); Vocal Volume scores increased from M=55.34 (SD±4.96) to M=60.79 (SD±6.26); PDQ-39 scores decreased from M=43.75 (SD±17.96) to M=37.01 (SD±18.57). Conclusions: Neurorehabilitation is integral in the holistic treatment of PD as medications have limited efficacy in advanced stages of this progressive disease. Although uncontrolled, the study indicates that individualized, multimodal rehabilitation intervention in moderately advanced PD has a global effect on function. Disclosure: Dr. Moondra has nothing to disclose. Dr. Persaud has nothing to disclose. Ms. Claro has nothing to disclose. Mrs. Mccrossin has nothing to disclose. Dr. Rubin has nothing to disclose. Dr. Di Rocco has nothing to disclose.
- 25 April 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (17_supplem)
Functional Outcomes of an Intensive Multimodal Rehabilitation Intervention for Moderately Advanced Parkinson's Disease (P10-11.004)
Objective: To measure the impact of intensive multimodal neurorehabilitation in patients with moderately advanced with Parkinson’s disease (PD) Background: Dedicated neurorehabilitation is an essential part of the comprehensive care regimen for PD patients. Intensive multimodal therapy may be especially efficacious for motor and non-motor symptoms in moderately advanced patients, who are at higher risk of falling and losing independent function. Few studies have been conducted in inpatient setting, where pharmacological intervention and therapies can be personalized. Here we present initial functional and quality of life outcomes for patients who participated in our tailored rehabilitation program. Design/Methods: 120 patients with PD (H&Y Stage 3–4) were admitted to the Parkinson’s neurorehabilitation unit. Admission criteria included loss of independence in key life function and falls within the past year. Patients participated in a structured inpatient, personalized multidisciplinary program with an emphasis on physical, occupational, and speech therapies. The patients were also followed by Movement Disorders specialists, who tailored pharmacotherapy. Average length of stay in the program was 14.8 days. A variety of clinical and self-reported scales were completed at admission and discharge: Beck’s Depression Inventory (BDI), Sleep Scale (PDSS), Timed Up and Go (TUG), Vocal Volume, and Parkinson’s Disease Questionnaire (PDQ-39). The statistical methods utilized were two-sample paired t-tests and correlation analyses. Results: The following results were statistically significant (p≤0.05): BDI scores decreased from M=16.64 (SD±10.83) to M=12.98 (SD±9.34); PDSS scores increased from M=88.12 (SD±26.30) to M=105.5 (SD±24.47); TUG scores decreased from M=57.46 (SD±47.50) to M=40.59 (SD±33.75); Vocal Volume scores increased from M=55.34 (SD±4.96) to M=60.79 (SD±6.26); PDQ-39 scores decreased from M=43.75 (SD±17.96) to M=37.01 (SD±18.57). Conclusions: Neurorehabilitation is integral in the holistic treatment of PD as medications have limited efficacy in advanced stages of this progressive disease. Although uncontrolled, the study indicates that individualized, multimodal rehabilitation intervention in moderately advanced PD has a global effect on function. Disclosure: Dr. Moondra has nothing to disclose. Dr. Persaud has nothing to disclose. Ms. Claro has nothing to disclose. Mrs. Mccrossin has nothing to disclose. Dr. Rubin has nothing to disclose. Dr. Di Rocco has nothing to disclose.
- 1 January 2019
- Published by Elsevier in Journal of Affective Disorders
- Vol. 242, 29-38
Divergent associations between ghrelin and neural responsivity to palatable food in hyperphagic and hypophagic depression
- 1 January 2019
- Published by Elsevier in Journal of Affective Disorders
- Vol. 242, 29-38
Divergent associations between ghrelin and neural responsivity to palatable food in hyperphagic and hypophagic depression